You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


FDA clears Keytruda for first-line cervical cancer

MSD’s PD-1 inhibitor Keytruda (pembrolizumab) has received approval from the US Food and Drug Administration (FDA) for the first-line treatment of certain cervical cancer patients.